文献速递神经免疫

自体造血干细胞移植治疗多发性硬化:一项荟萃分析

Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis.
PubMed 文献 · Neurology · 2017-04-28

复发缓解型且残疾程度较低的患者获益风险比最佳。

要点

  • 移植相关死亡率为2.1%,较早研究及复发缓解型比例低的研究中更高。
  • 2年疾病进展率为17.1%,5年为23.3%,复发缓解型比例高者2年进展率更低。
  • 2年无疾病活动证据比例为83%,5年为67%。

核心结论

  • 对于侵袭性复发缓解型且尚未累积高残疾水平的多发性硬化患者,该疗法的获益风险比最大。

主要发现

  • 移植相关死亡率的合并估计值为2.1%(95%CI 1.3%-3.4%)。
  • 移植相关死亡率在较早的研究中更高(p=0.014),在复发缓解型患者比例较低的研究中更高(p=0.028)。
  • 基线扩展残疾状态量表评分较高与移植相关死亡率更高显著相关(p=0.013)。
  • 2年疾病进展率的合并值为17.1%(95%CI 9.7%-24.5%),5年为23.3%(95%CI 16.3%-31.8%)。
  • 2年无疾病活动证据的患者比例为83%(范围70%-92%),5年为67%(范围59%-70%)。

关键数值与推荐

  • 2年疾病进展率较低与复发缓解型患者比例较高显著相关(p=0.004)。

临床怎么用

  • 对于侵袭性复发缓解型且残疾程度尚低的多发性硬化患者,可考虑自体造血干细胞移植以获取最大获益风险比。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To summarize the evidence on immunoablative therapy followed by autologous hematopoietic stem cell transplantation (aHSCT) to manage severe and treatment-refractory multiple sclerosis (MS). METHODS: We collected all the published studies of aHSCT in any form of MS from 1995 to 2016, carefully excluding reports that were updated in subsequent studies. Endpoints were transplant-related mortality (TRM), rate of disease progression, and no evidence of disease activity (NEDA) status. A weighted metaregression based on a Poisson model was run, assessing whether there were study-specific characteristics with an effect on TRM and progression. RESULTS: Fifteen studies including 764 transplanted patients were pooled in the meta-analysis. The pooled estimate of TRM was 2.1% (95% confidence interval [CI] 1.3%-3.4%). TRM was higher in older studies (p = 0.014) and in studies with a lower proportion of patients with relapsing-remitting MS (RRMS) (p = 0.028). A higher baseline Expanded Disability Status Scale (p = 0.013) was also significantly associated with a higher TRM. Pooled rate of progression was 17.1% at 2 years (95% CI 9.7%-24.5%) and 23.3% (95% CI 16.3%-31.8%) at 5 years. Lower 2-year progression rate was significantly associated with higher proportions of patients with RRMS (p = 0.004). The pooled proportion of NEDA patients at 2 years was 83% (range 70%-92%) and at 5 years was 67% (range 59%-70%). CONCLUSIONS: The emerging evidence on this therapeutic approach in MS indicates that the largest benefit/risk profile form this therapeutic approach can be obtained in patients with aggressive MS with a relapsing-remitting course and who have not yet accumulated a high level of disability.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Sormani MP, Muraro PA, Schiavetti I, et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis. Neurology. 2017. PMID: 28455383. doi:10.1212/WNL.0000000000003987

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。